News
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has ...
We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Merck & Co., Inc. stands seventh on our list and recently ...
Initiating Rapid Micro Biosystems at 'buy' with $4.60 fair value, driven by strong growth potential in automated microbial ...
For $10 billion, Merck is acquiring a promising healthcare company which is in the early stages of its growth. Key to its ...
Merck & Company, Inc. (NYSE:MRK) is one of the high-margin pharma stocks to buy now. Jefferies has raised its price target on ...
Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find out why I rate MRK a Buy.
The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...
On July 9, Merck announced that it would acquire Verona Pharma, a U.K.-based biotechnology company specializing in the development of medicines for respiratory diseases. Merck will pay $10 billion in ...
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an ...
The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.
Merck & Co., Inc is a global healthcare leader company engaged in the discovery, identification, and development of advanced treatment for cancer and various diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results